If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
=== Archaea === In 2022, the discovery of serotonin N-acetyltransferase (SNAT)—the penultimate, rate-limiting enzyme in the melatonin biosynthetic pathway—in the archaeon Thermoplasma volcanium firmly places melatonin biosynthesis in all three major domains of life, dating back to ~4 Gya.
Computational techniques complement the chemoproteomic toolkit as parallel lines of evidence supporting potential drug-target pairs, and are used to generate structural models that inform lead optimization. Several targets of high profile drugs have been identified using chemoproteomics, and the continued improvement of mass spectrometer sensitivity and chemical probe technology indicates that chemoproteomics will play a large role in future drug discovery.
Electron-capture dissociation (ECD), collisional-induced dissociation (CID), and infrared multiphoton dissociation (IRMPD) are all utilized to produce fragment spectra in tandem mass spectrometry experiments. Although CID and IRMPD use vibrational excitation to further dissociate peptides by breaking the backbone amide linkages, which are typically low in energy and weak, CID and IRMPD may also cause dissociation of post-translational modifications. ECD, on the other hand, allows specific modifications to be preserved. This is quite useful in analyzing phosphorylation states, O- or N-linked glycosylation, and sulfating. FTICR-MS are also applied increasingly in study of fusion plasma, which is primarily made up of hydrogen and helium between masses 2-4. FTICR-MS resolution scales inversely with particle mass, meaning that even a rugged mass spectrometer can achieve very high accuracy at these low masses. While many FTICRs employ superconducting magnets to reach 7-21 T field strengths and extreme resolutions, permanent magnet FTICRs on the order of 1 T field strengths still provide plentiful resolution for fusion applications while shrinking costs and cooling infrastructure.
== See also == Black box Bus analyzer Computer data logging: logging APIs, server logs & syslog, web logging & web counters Continuous emissions monitoring system Runtime intelligence Sequence of events recorder SensorML Shock and vibration data logger Temperature data logger
purple passion fruit (fruits of Passiflora edulis Sims) yellow passion fruit (Passiflora edulis f. flavicarpa Deg.) sweet granadilla (Passiflora ligularis) giant granadilla (Passiflora quadrangularis L.) banana passion fruit (fruits of Passiflora tarminiana)
Sources: en.wikipedia.org
=== Management of acute flare === During moderate or severe symptomatic attacks, a short course (usually 3–5 days) of high doses of corticosteriods is the usual approach. Initially, oral corticosteroids are used; if that is ineffective, an intravenous course can be tried. Milder attacks may not need treatment. Although targeted at acute attacks, they might also have a small longer-term benefit. Severe attacks that do not respond to corticosteroids might be treatable by plasma exchange.
The split and pool (split-mix) synthesis is a method in combinatorial chemistry that can be used to prepare combinatorial compound libraries. It is a stepwise, highly efficient process realized in repeated cycles. The procedure makes it possible to prepare millions or even trillions of compounds as mixtures that can be used in drug research.
=== Controversy and conservation issues === The use and trade of elephant ivory have become controversial because they have contributed to seriously declining elephant populations in many countries. It is estimated that consumption in Great Britain alone in 1831 amounted to the deaths of nearly 4,000 elephants. In 1975, the Asian elephant was placed on Appendix I of the Convention on International Trade in Endangered Species (CITES), which prevents international trade between member states of species that are threatened by trade. The African elephant was placed on Appendix I in January 1990. Since then, some southern African countries have had their populations of elephants "downlisted" to Appendix II, allowing the domestic trade of non-ivory items; there have also been two "one off" sales of ivory stockpiles. In June 2015, more than a ton of confiscated ivory was crushed in New York City's Times Square by the Wildlife Conservation Society to send a message that the illegal trade will not be tolerated. The ivory, confiscated in New York and Philadelphia, was sent up a conveyor belt into a rock crusher. The Wildlife Conservation Society has pointed out that the global ivory trade leads to the slaughter of up to 35,000 elephants a year in Africa. In June 2018, Conservative MEPs' Deputy Leader Jacqueline Foster MEP urged the EU to follow the UK's lead and introduce a tougher ivory ban across Europe. China was the biggest market for poached ivory but announced they would phase out the legal domestic manufacture and sale of ivory products in May 2015.
Evidence from reviews of benzodiazepine tolerance mechanisms and clonazepam use in psychiatric disorders contrasts with clinical guidelines that benzodiazepines lose anxiolytic efficacy over weeks; these reviews present RCT evidence of continued anxiolytic efficacy at up to 22 weeks and observational (open-label) evidence of continued efficacy at up to 3 years. A 2015 review found a larger effect with medications than with talk therapy. Medications with benefit include serotonin-noradrenaline reuptake inhibitors, benzodiazepines, and selective serotonin reuptake inhibitors.
In August 2008, Obama and Biden met in secret to discuss the possibility of a place for Biden in the Obama administration, and developed a strong personal rapport. On August 22, Obama announced that Biden would be his running mate. The New York Times reported that the choice reflected a desire for someone with foreign policy and national security experience. Others pointed out Biden's appeal to middle-class and blue-collar voters. Biden was officially nominated for vice president on August 27 at the 2008 Democratic National Convention in Denver. Biden's vice-presidential campaigning gained little media attention, as the press devoted far more coverage to the Republican nominee and then-governor of Alaska, Sarah Palin. Under instructions from the campaign, Biden kept his speeches succinct and tried to avoid offhand remarks. Privately, Biden's remarks frustrated Obama. "How many times is Biden gonna say something stupid?", he once angrily asked. Obama campaign staffers called Biden's blunders "Joe bombs" and kept Biden uninformed about strategy discussions, which irked Biden. Relations between the two campaigns became strained for a month, until Biden apologized to Obama and the two built a stronger partnership. As the 2008 financial crisis reached a peak in September 2008, and the proposed Emergency Economic Stabilization Act of 2008 became a major factor in the campaign, Biden voted for the $700 billion Emergency Economic Stabilization Act of 2008, which passed in the Senate.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.